13 - How to Treat Difficult Mold Infections

Monday, October 20, 2025

8:00 AM - 9:00 AM US ET

Location: B206

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit
ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

SH

Sarah Hammond, MD (she/her/hers)

Director of Hematology/Oncology Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Boston, MA, United States
Paschalis Vergidis, MD, MS, FIDSA (he/him/his)

Associate Professor of Medicine, Director of Hematology/Oncology Infectious Diseases
Mayo Clinic
Rochester, MN, United States

Faculty(s)

DF

Dimitrios Farmakiotis

Beth-Israel Deaconess Medical Center
Paschalis Vergidis, MD, MS, FIDSA (he/him/his)

Associate Professor of Medicine, Director of Hematology/Oncology Infectious Diseases
Mayo Clinic
Rochester, MN, United States

Disclosure(s):

Sarah P. Hammond, MD: Cidara: Grant/Research Support; F2G: Grant/Research Support; GSK: Grant/Research Support; Melinta: Advisor/Consultant; Mundipharma: Grant/Research Support; Pfizer: Advisor/Consultant; Roche: Advisor/Consultant; Scynexis: Grant/Research Support; Seres Therapeutics: Advisor/Consultant; Takeda: Advisor/Consultant; Treeline Biotherapeutics: Advisor/Consultant

Paschalis Vergidis, MD, MS, FIDSA: Ansun Biopharma: Grant/Research Support; F2G Limited: Grant/Research Support; Merck and Co: Honoraria; Mundipharma: Grant/Research Support; Scynexis Inc.: Advisor/Consultant, Grant/Research Support; Zepto Life Technology: Grant/Research Support

Dimitrios Farmakiotis: Astellas Pharma Inc.: Grant/Research Support; AstraZenca: Grant/Research Support; Eurofins Viracor: Advisor/Consultant, Grant/Research Support, Honoraria; Merck and Company, Inc.: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss evidence-based antifungal treatment approach to invasive aspergillosis;
discuss drug toxicities and important drug interactions associated with oral azoles approved for the treatment of Aspergillosis that influence treatment choice;
discuss evidence-based antifungal treatment approach to mucormycosis.

Presentations:

8:00 AM - 8:30 AM US ET

Mucorales: Is There Evidence for Dual Antifungal Therapy or High-Dose Liposomal Amphotericin?
Speaker: Dimitrios Farmakiotis – Beth-Israel Deaconess Medical Center
8:30 AM - 9:00 AM US ET

Aspergillosis: What Is the Best Agent for Treatment in 2025?
Speaker: Paschalis Vergidis, MD, MS, FIDSA (he/him/his) – Mayo Clinic